Announced
Financials
Sources
Tags
Private
Pending
Acquisition
Single Bidder
pharmaceutical company
Majority
Pharmaceuticals
Domestic
Friendly
India
Synopsis
Piramal Pharma, an Indian pharmaceutical giant, agreed to acquire Hemmo Pharmaceuticals, a synthetic peptide API manufacturer, for $105m. “Hemmo has demonstrated excellence and a great quality track record with a differentiated and hard to replicate capability. Once welcomed into the PPL family, it will be another example of a distinctive offering to attract and delight customers. This is the third Pharma acquisition this fiscal year, and yet another example of the implementation of our profitable growth strategy," Nandini Piramal, Piramal Pharma Chairperson.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.